Herein, we found both low (20 mg/kg/d, equivalent to approximately 1.6 mg/kg for human) and high dose (60 mg/kg/d, equivalent to approximately 4.8 mg/kg for human) of LY supplementation remarkably reduced body weight gain, ameliorated serum dyslipidemia, decreased serum levels of ALT and inhibited hepatic TG accumulation in the HFFD -fed rats, indicating the protective effect of LY on NAFLD. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.